Does hepatitis B virus therapy reduce the risk of hepatocellular carcinoma? - Wikidata - awgldk - TriplyDB

Does hepatitis B virus therapy reduce the risk of hepatocellular carcinoma?

Does hepatitis B virus therapy reduce the risk of hepatocellular carcinoma?

http://www.wikidata.org/entity/Q38303237

about

Long Non-Coding RNAs in Hepatitis B Virus-Related Hepatocellular Carcinoma: Regulation, Functions, and Underlying Mechanisms.Hepatitis B virus treatment in hepatocellular carcinoma patients prolongs survival and reduces the risk of cancer recurrence

P2860

Q45324358-46602895-9053-45AF-A726-4209294013E1 Q57494336-7BF3A89F-F240-4A24-9271-7BAE798B3C40

P2860

Does hepatitis B virus therapy reduce the risk of hepatocellular carcinoma?

http://www.wikidata.org/entity/Q38303237

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Does hepatitis B virus therapy reduce the risk of hepatocellular carcinoma?

@en

type

label

Does hepatitis B virus therapy reduce the risk of hepatocellular carcinoma?

@en

prefLabel

Does hepatitis B virus therapy reduce the risk of hepatocellular carcinoma?

@en

P1433

Q38303237-6C17459A-4422-4F00-B68B-1BE5CA9C2095

P1476

Q38303237-432562CD-C392-4C5A-B46F-7047027E15F6

P2093

Q38303237-82EA8C32-7BAE-4C3C-A1FE-C9165E4DC302

P2860

Q38303237-09BC1253-64D4-473F-8F9B-32BB699D93D2

Q38303237-1319BF8F-13D4-4446-AEC2-39E4224BB935

Q38303237-19F2358C-E1B1-4400-B1D8-CD63212F604F

Q38303237-1D3730C1-AB17-4088-B621-2E2922DA470E

Q38303237-1F575558-4316-4193-A699-BDDBE4E9275C

Q38303237-212C6686-215B-4544-AE6F-916ABBC4EA44

Q38303237-24B8BAB0-C15B-4D1E-9AC5-44944635D5DD

Q38303237-271EA9B2-69D6-4418-AF70-E6B75115304B

Q38303237-274509C6-D566-4006-A459-B5CA37623527

Q38303237-292C8566-A67D-4D11-B783-F2371A52F8B1

P304

Q38303237-1ED92045-C00E-42E5-964F-302B943BB906

P31

Q38303237-E4B09AAF-21CA-434C-BE09-9C39A563A1E5

P356

Q38303237-4CEBBE02-0D5F-476A-B3D1-4B9D9A7DFD48

P407

Q38303237-EA968679-079F-438B-A564-F2B3EA419B0B

P433

Q38303237-B38E8F2A-A644-4FA9-9C53-2F8EE582D9D4

P478

Q38303237-5C7A8EBF-8068-4199-8288-06924CB2D921

P50

Q38303237-54315019-CD38-41AD-BD97-8FD245EA376E

P577

Q38303237-F40ED43A-C367-405A-8DB9-398FD91CD558

P698

Q38303237-2D931E52-2952-4A1A-9107-780BAD994689

P356

14740338.2015.998649

P1433

Expert Opinion on Drug Safety

P1476

Does hepatitis B virus therapy reduce the risk of hepatocellular carcinoma?

@en

P2093

Ezequiel Ridruejo

http://www.w3.org/2001/XMLSchema#string

P2860

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

Chronic hepatitis B: update 2009

Association of adjuvant antiviral therapy with risk of cancer progression and deaths in patients with hepatitis-B-virus-related hepatocellular carcinoma following curative treatment: a nationwide cohort study

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.

Lamivudine for patients with chronic hepatitis B and advanced liver disease.

Long-term nucleos(t)ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications: a meta-analysis

Prevention of hepatitis B virus-related hepatocellular carcinoma.

Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors.

P304

439-451

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14740338.2015.998649

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-12-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25547687

http://www.w3.org/2001/XMLSchema#string